Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

(2010) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

(2009) K. L. Blackwell et al.   ANNALS OF ONCOLOGY

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety and biomarker results from Japanese patients phase II studies

(2009) M Toi et al.   BRITISH JOURNAL OF CANCER

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

(2009) Y H Park et al.   BRITISH JOURNAL OF CANCER

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Lapatinib

(2009) James E. Frampton   DRUGS

Cixutumumab

(2009) Kevin P McKian et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Comparison of Time Trends in Breast Cancer Incidence (1973-2002) in Asia, from Cancer Incidence in Five Continents, Vols IV-IX

(2009) Y. Hirabayashi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer

(2008) B. Paul et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

(2008) S. Dawood et al.   ANNALS OF ONCOLOGY

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

(2008) H. J. Burstein et al.   ANNALS OF ONCOLOGY

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

(2008) Alessandra Fabi et al.   BREAST

Analysis of dermatologic events in patients with cancer treated with lapatinib

(2008) M. E. Lacouture et al.   BREAST CANCER RESEARCH AND TREATMENT

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

(2008) John P. Crown et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

HER-2-positive metastatic breast cancer: trastuzumab and beyond

(2008) Giulio Metro et al.   EXPERT OPINION ON PHARMACOTHERAPY

In Reply:

(2008) David J. Brenner et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2008) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain

(2008) B. Gril et al.   JNCI-Journal of the National Cancer Institute